X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

SRNE

Closed

Sorrento Therape

0.0014
0.0000 (0.00%)
Last Update: 01 Jul 2025 18:49:00
Yesterday: 0.0014
Day's Range: 0.0014 - 0.0014
Send
When Written:
 
0.3566
Sorrento Therapeutics is a biopharmaceutical company that develops and commercializes innovative therapies for the treatment of cancer, autoimmune, inflammatory, and neurodegenerative diseases. The company's primary focus is on developing antibody-based therapies that target specific proteins and pathways involved in disease progression.

Sorrento Therapeutics has a diverse pipeline of product candidates, including CAR-T cell therapies, monoclonal antibodies, and small molecule inhibitors. The company's lead product candidate is a CAR-T cell therapy for the treatment of multiple myeloma, which is currently in clinical trials.

In addition to its internal pipeline, Sorrento Therapeutics has a number of collaborations and partnerships with other companies and research institutions. The company's goal is to leverage its expertise in antibody development and immune modulation to create new and effective therapies for patients with unmet medical needs.

Sorrento Therapeutics is headquartered in San Diego, California, and has operations in China, Korea, and other countries. The company was founded in 2006 and went public in 2013.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X